Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol
The DOI matches its Crossref record; 136 of the 137 references it cites were found in a registry or an index.
Abstract
Notwithstanding the effectiveness of lowering LDL cholesterol, residual CVD risk remains in high-risk populations, including patients with diabetes, likely contributed to by non-LDL lipid abnormalities. In this Perspectives in Diabetes article, we emphasize that changing demographics and lifestyles over the past few decades have resulted in an epidemic of the “atherogenic dyslipidemia complex,” the main features of which include hypertriglyceridemia, low HDL cholesterol levels, qualitative changes in LDL particles, accumulation of remnant lipoproteins, and postprandial hyperlipidemia. We briefly review the underlying pathophysiology of this form of dyslipidemia, in particular its association with insulin resistance, obesity, and type 2 diabetes, and the marked atherogenicity of this condition. We explain the failure of existing classes of therapeutic agents such as fibrates, niacin, and cholesteryl ester transfer protein inhibitors that are known to modify components of the atherogenic dyslipidemia complex. Finally, we discuss targeted repurposing of existing therapies and review promising new therapeutic strategies to modify the atherogenic dyslipidemia complex. We postulate that targeting the central abnormality of the atherogenic dyslipidemia complex, the elevation of triglyceride-rich lipoprotein particles, represents a new frontier in CVD prevention and is likely to prove the most effective strategy in correcting most aspects of the atherogenic dyslipidemia complex, thereby preventing CVD events.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Insulin resistance with increased circulating FAs and decreased insulin signalling can also lead to increased chylomicron secretion.15”
From Clinical review on triglycerides (2020) · cites this paper as [15]
In the citing paper
“This milieu drives increased VLDL secretion, which is particularly enhanced when FA and insulin are in excess.15”
From Clinical review on triglycerides (2020) · cites this paper as [15]
Citations
Cites
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. Z. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,295
Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66378-7 · Cited by 5,550
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Cited by
Palmitic and Oleic Acid: The Yin and Yang of Fatty Acids in Type 2 Diabetes Mellitus
Palomer, X., Pizarro-Delgado, J., Barroso, E., & Vázquez-Carrera, M. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.11.009 · Cited by 548
Clinical review on triglycerides
Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz785 · Cited by 544
“15 Furthermore, hyperglycaemia stimulates, while glucagon-like peptide 1 inhibits chylomicron secretion.”
BackgroundSelf-citationA Modern Approach to Dyslipidemia
Berberich, A. J., & Hegele, R. A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab037 · Cited by 469
“CHL also largely overlaps with the so-called “atherogenic dyslipidemia complex,” which is associated with obesity, insulin resistance, and type 2 diabetes (227); this association reinforces the important role of secondary factors underlying this phenotype.”
BackgroundSelf-citationDuran, E. K., Aday, A. W., Cook, N. R., Buring, J. E., Ridker, P. M., & Pradhan, A. D. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.02.059 · Cited by 334
PPAR Agonists and Metabolic Syndrome: An Established Role?
Botta, M., Audano, M., Sahebkar, A., Sirtori, C., Mitro, N., & Ruscica, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041197 · Cited by 253
“The role of fibrates in the clinical management of disorders characterized by elevated TGs is now well established [60].”
BackgroundRemnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease
Chait, A., Ginsberg, H. N., Vaisar, T., Heinecke, J. W., Goldberg, I. J., & Bornfeldt, K. E. (2020) · Diabetes · doi:10.2337/dbi19-0007 · Cited by 229
“The hallmark of dyslipidemia in T2MD is high plasma triglycerides and low HDL-C.”
BackgroundInfluentialA Renewed Focus on the Association Between Thyroid Hormones and Lipid Metabolism
Duntas, L. H., & Brenta, G. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00511 · Cited by 217
“Residual CVD risk is mainly determined by hypertriglyceridemia, elevated small dense LDL particles, reduced HDL-C and HDL particle numbers, increased triglyceride (TG)–rich lipoproteins or remnant lipoproteins (RLPs) and postprandial hyperlipidemia, also known collectively as the atherogenic dyslipidemia complex (32).”
BackgroundUnmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management
Ganda, O. P., Bhatt, D. L., Mason, R. P., Miller, M., & Boden, W. E. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.061 · Cited by 195
“However, even among patients treated with high-intensity statins, residual risk persists, particularly in high-risk subjects with pre-existing ASCVD, T2DM, or metabolic syndrome (5,8).”
BackgroundInfluentialNussbaumerova, B., & Rosolova, H. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01167-2 · Cited by 173
“Individuals with abdominal obesity often present an increase in small dense LDL resulting in an increased number of LDL particles [6 • , 7, 8].”
The Complex Interactions Between Obesity, Metabolism and the Brain
Uranga, R. M., & Keller, J. N. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00513 · Cited by 164
Aday, A. W., Lawler, P. R., Cook, N. R., Ridker, P. M., Mora, S., & Pradhan, A. D. (2018) · Circulation · doi:10.1161/circulationaha.118.035432 · Cited by 140
Varbo, A., & Nordestgaard, B. G. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000429 · Cited by 135
Cholesterol metabolism, pancreatic β-cell function and diabetes
Perego, C., Da Dalt, L., Pirillo, A., Galli, A., Catapano, A. L., & Norata, G. D. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.04.012 · Cited by 135
Biological Consequences of Dysfunctional HDL
Pirillo, A., Catapano, A. L., & Norata, G. D. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180530110543 · Cited by 134
Natural products for controlling hyperlipidemia: review
El-Tantawy, W. H., & Temraz, A. (2018) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2018.1441315 · Cited by 132
Genetics of Triglycerides and the Risk of Atherosclerosis
Dron, J. S., & Hegele, R. A. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0667-9 · Cited by 110
Self-citationHuh, J. H., Han, K.-D., Cho, Y. K., Roh, E., Kang, J. G., Lee, S. J., & Ihm, S.-H. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01667-6 · Cited by 106
“These traits have been associated with increased CVD risk [4].”
BackgroundSun, J., Wang, Z., Chen, L., & Sun, G. (2021) · Antioxidants · doi:10.3390/antiox10081309 · Cited by 90
“As a metabolic disease with abnormal blood lipid levels, hyperlipidemia is an important risk factor for many complications and increases the incidence and mortality of cardiovascular diseases [23,24].”
BackgroundDyslipidemia Management in Adults With Diabetes
Lazarte, J., & Hegele, R. A. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.07.003 · Cited by 98
Self-citationBoden, W. E., Bhatt, D. L., Toth, P. P., Ray, K. K., Chapman, M. J., & Lüscher, T. F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz778 · Cited by 72
“and small dense LDL particles, but also with elevated levels of serum triglycerides (TG), low levels of high-density lipoprotein cholesterol (HDL-C), and increased remnant lipoproteins.(1,3,6) It is also important to underscore that, despite intensive treatment with statins as well as newer and more powerful therapies…”
BackgroundMonocytes and macrophages as protagonists in vascular complications of diabetes
Kanter, J. E., Hsu, C.-C., & Bornfeldt, K. E. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00010 · Cited by 76
“This lipid profile, commonly referred to as diabetic dyslipidemia (13), is most often seen in subjects with T2DM, less well-controlled T1DM, or in subjects with T1DM with additional traits of metabolic syndrome (3).”
BackgroundRecent advances in triacylglycerol mobilization by the gut
Xiao, C., Stahel, P., Carreiro, A. L., Buhman, K. K., & Lewis, G. F. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.12.001 · Cited by 77
Self-citationStahel, P., Xiao, C., Hegele, R. A., & Lewis, G. F. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.007 · Cited by 75
Self-citationLipid Lowering Drugs: Present Status and Future Developments
Ruscica, M., Ferri, N., Santos, R. D., Sirtori, C. R., & Corsini, A. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00918-3 · Cited by 73
Levin, M. G., Zuber, V., Walker, V. M., Klarin, D., Lynch, J., Malik, R., Aday, A. W., Bottolo, L., Pradhan, A. D., Dichgans, M., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.053797 · Cited by 65
“38 Various mechanisms have been proposed to explain this relationship, including increased ability of small LDL particles to penetrate the arterial wall and increased susceptibility to oxidation.”
Huang, H., Guo, Y., Liu, Z., Zeng, Y., Chen, Y., & Xu, C. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac283 · Cited by 69
New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
Lorenzatti, A. J., & Toth, P. P. (2020) · European Cardiology Review · doi:10.15420/ecr.2019.06 · Cited by 72
Jiang, X., Pan, D., Zhang, T., Liu, C., Zhang, J., Su, M., Wu, Z. F., Zeng, X., Sun, Y., & Guo, Y. (2020) · Journal of Dairy Science · doi:10.3168/jds.2019-17586 · Cited by 63
Triglyceride lowering by omega-3 fatty acids: a mechanism mediated by N-acyl taurines
Bornfeldt, K. E. (2021) · Journal of Clinical Investigation · doi:10.1172/jci147558 · Cited by 58
Zhou, X., Ren, F., Hong Kui, W. E. I., Liu, L., Shen, T., Xu, S., Wei, J., Ren, J., & Ni, H. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0628-x · Cited by 59
“Hyperlipidemia is an abnormality of lipid metabolism, characterized by an elevation of total cholesterol (TC), triglyceride (TG), and low density lipoprotein-cholesterol (LDL-C), and/or a decreasing of high density lipoproteincholesterol (HDL-C) in circulating levels [1].”
Toth, P. P., Fazio, S., Wong, N. D., HULL, M. L., & Nichols, G. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13921 · Cited by 69
Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes
Khavandi, M., Duarte, F., Ginsberg, H. N., & Reyes‐Soffer, G. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0818-1 · Cited by 66
Insights into the pivotal role of statins and its nanoformulations in hyperlipidemia
Singh, S., Zahoor, I., Sharma, N., Behl, T., Kanojia, N., Sehgal, A., Mohan, S., Almoshari, Y., Salawi, A., Aleya, L., et al. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-23043-3 · Cited by 57
The LipoGlo reporter system for sensitive and specific monitoring of atherogenic lipoproteins
Thierer, J. H., Ekker, S. C., & Farber, S. A. (2019) · Nature Communications · doi:10.1038/s41467-019-11259-w · Cited by 58
High-Density Lipoprotein Function in Cardiovascular Disease and Diabetes Mellitus
He, Y., Kothari, V. M., & Bornfeldt, K. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310222 · Cited by 57
“Among these, dyslipidemia characterized by a low level of HDL-C (high-density lipoprotein cholesterol) is strongly and inversely correlated with CVD risk, and low HDL-C levels is part of the atherogenic dyslipidemia complex associated with diabetes mellitus.(5) These observations triggered intense interest in increasi…”
BackgroundBartolo, B. A. D., Cartland, S. P., Genner, S. W., Cholan, P. M., Vellozzi, M., Rye, K., & Kavurma, M. M. (2021) · Journal of Diabetes Research · doi:10.1155/2021/6668506 · Cited by 57
“Diabetic patients have elevated plasma levels of low-density lipoprotein (LDL) and triglycerides and low levels of high-density lipoprotein (HDL) [4].”
BackgroundReijnders, E., van der Laarse, A., Jukema, J. W., & Cobbaert, C. M. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1264319 · Cited by 60
Atherogenic Dyslipidemia and Residual Vascular Risk After Stroke or Transient Ischemic Attack
Hoshino, T., Ishizuka, K., Toi, S., Mizuno, T., Nishimura, A., Takahashi, S., Wako, S., & Kitagawa, K. (2021) · Stroke · doi:10.1161/strokeaha.121.034593 · Cited by 49
Development of the novel ACLY inhibitor 326E as a promising treatment for hypercholesterolemia
Xie, Z., Zhang, M., Song, Q., Cheng, L., Zhang, X., Song, G., Sun, X., Gu, M., Zhou, C., Zhang, Y., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.06.011 · Cited by 47
Botteri, G., Montori-Grau, M., Gumà, A., Pizarro‐Delgado, J., Cedó, L., Escolá‐Gil, J. C., Li, D., Barroso, E., Palomer, X., Kohan, A. B., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4401-5 · Cited by 44
“Introduction Insulin resistance and type 2 diabetes mellitus are characterised by the presence of atherogenic dyslipidaemia, which includes the following cluster of abnormalities: high levels of triacylglycerols, low levels of HDL-cholesterol and the appearance of small, dense LDLs [1].”
Morrow, N. M., Trzaskalski, N. A., Hanson, A. A., Fadzeyeva, E., Telford, D. E., Chhoker, S. S., Sutherland, B. G., Edwards, J. Y., Huff, M. W., & Mulvihill, E. E. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316896 · Cited by 42
Impact of Red Yeast Rice on Metabolic Diseases: A Review of Possible Mechanisms of Action
Ju, H., Wang, J., Gan, Q., Ran, Q., Lou, G., Xiong, H., Peng, C., Sun, J.-L., Yao, R., & Huang, Q. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.0c01893 · Cited by 39
Role of the Gut in Diabetic Dyslipidemia
Stahel, P., Xiao, C., Nahmias, A., & Lewis, G. F. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00116 · Cited by 37
“We have previously reviewed the effects of incretin therapies on intestinal lipoprotein metabolism (93).”
BackgroundSelf-citationHeidari, A. (2020) · Advanced Science Engineering and Medicine · doi:10.1166/asem.2020.2635 · Cited by 38
Omega-3 fatty acids for cardiovascular event lowering
Kaur, G., Mason, R. P., Steg, P. G., & Bhatt, D. L. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae003 · Cited by 47
Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis
Lee, C., Liao, C., Meng, S., Wu, W., Chiang, J., & Wu, M. (2021) · Biomedicines · doi:10.3390/biomedicines9080985 · Cited by 46
“Metabolic syndrome may increase VLDL levels, especially when free acids and insulin accumulate in the circulation [70].”
BackgroundCardiovascular risk reduction with icosapent ethyl
Patel, P. N., Patel, S. M., & Bhatt, D. L. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000678 · Cited by 33
“However, even among patients with optimal LDL-C levels, residual risk persists, requiring research into the role of other dyslipidemias in contributing to the progression of ASCVD [3,4].”
BackgroundDevelopment and optimization of ezetimibe nanoparticles with improved antihyperlipidemic activity
Shukr, M. H., Ismail, S., & Ahmed, S. M. (2018) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2018.12.001 · Cited by 36
Zhu, Y., Chen, M., Liu, K., Gao, A., Kong, X., Liu, Y., Han, H., Li, H., Zhu, H., Zhang, J., et al. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63136 · Cited by 38
Li, S., Guo, Y., Zhao, X., Zhang, Y., Zhu, C., Wu, N., Xu, R., Qing, P., Gao, Y., Li, X., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-00499-9 · Cited by 38
Lin, L.-Y., Hsu, C., Lee, H.-A., Wang, W.-H., Kurniawan, A. L., & Chao, J. C.-J. (2019) · Nutrients · doi:10.3390/nu11040845 · Cited by 36
“As these two diseases have significant genetic components, individuals with a family history of dyslipidemia or hyperglycemia are at higher risk for developing these two diseases [1,2].”
BackgroundA Systematic Review and Meta-Analysis of Lipid Signatures in Post-traumatic Stress Disorder
Bharti, V., Bhardwaj, A., Elias, D. A., Metcalfe, A. W. S., & Kim, J. S. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.847310 · Cited by 33
Lu, J., Shang, X., Yao, B., Sun, D., Liu, J., Zhang, Y., Wang, H., Shi, J., Chen, H., Shi, T., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.08.005 · Cited by 40
Bagheri, P., Khalili, D., Seif, M., & Rezaianzadeh, A. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00716-7 · Cited by 30
“Secondly, it must be said that in this transition, there may be several biological and physiological mechanisms, such as the effect of thyroid hormones [64, 65], female hormone interactions in women [66] and the effect of preventive actions on other components on lipid profile [67, 68] that due to the interdependence…”
BackgroundMasood, S., Masood, O., Mujtaba, S. F., & Banerjee, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-4723-8_4 · Cited by 32
Accurate and Efficient Lipoprotein Detection Based on the HCR–DNAzyme Platform
Chen, H., Hu, Y., Yao, P., Ning, D., Zhang, Y.-P., Wang, Z., Liu, S., & Pang, D. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.0c05322 · Cited by 29
Feingold, K. R. (2015) · Europe PMC (PubMed Central) · Cited by 36
Scholz, G. H., & Hanefeld, M. (2016) · Visceral Medicine · doi:10.1159/000450866 · Cited by 29
Apolipoprotein A1 Forms 5/5 and 5/4 Antiparallel Dimers in Human High-density Lipoprotein
He, Y., Song, H. D., Anantharamaiah, G. M., Palgunachari, M. N., Bornfeldt, K. E., Segrest, J. P., & Heinecke, J. W. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra118.000878 · Cited by 29
“HDL’s biogenesis, metabolism, and function has been extensively investigated (3-5, 12-17).”
BackgroundPei, Z., Guo, Y., Zhu, H., Dong, M., Zhang, Q., & Wang, F. (2020) · BioMed Research International · doi:10.1155/2020/4878704 · Cited by 29
Jin, Q., Lau, E. S. H., Luk, A. O. Y., Tam, C. H. T., Ozaki, R., Lim, C. K. P., Wu, H., Chow, E., Kong, A. P. S., Lee, H. M., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06108-5 · Cited by 31
“Type 2 diabetes is characterised by atherogenic dyslipidaemia: elevated triglyceride-rich lipoproteins (TRLs) and reduced HDL, contributing to substantial residual risk despite optimal LDL-cholesterol (LDL-C) levels [5].”
BackgroundRemnant Cholesterol and Residual Risk of Atherosclerotic Cardiovascular Disease
Li, X., Li, Z.-F., & Wu, N. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm25985 · Cited by 30
“Lipoproteins, such as triglyceride-rich lipoproteins (TRLs), which are not typically addressed in standard lipid-lowering therapies, may explain this residual risk [4].”
Residual cardiovascular risk among people with diabetes
Dash, S., & Leiter, L. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13646 · Cited by 27
“Concordant with this hypothesis, in the STENO-2 trial patients with T2D and microalbuminuria receiving treatments targeting multiple cardiac risk factors had dramatic lower mortality and CVD.15 Intensively treated patients lower received low dose aspirin and renin-angiotensin system blockade (irrespective of blood pre…”
BackgroundResultInfluentialSelf-citationEmerging Targets for Cardiovascular Disease Prevention in Diabetes
Stitziel, N. O., Kanter, J. E., & Bornfeldt, K. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.03.011 · Cited by 30
Gómez-Álvarez, E., Verdejo, J., Ocampo, S., Ponte-Negretti, C. I., Ruíz, E., & Ríos, M. M. (2020) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2020.100545 · Cited by 27
“Secondly, the different components of AD often present as a cluster because they share metabolic and physiopathological mechanisms, and therefore the polypill strategy might have improved multiple components simultaneously [33].”
BackgroundManaging dyslipidemia in patients with Type 2 diabetes
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1912734 · Cited by 32
“elevated levels of remnant lipoproteins and postprandial hyperlipidemia which often coexist [11].”
BackgroundHieronimus, B., Griffen, S. C., Keim, N. L., Bremer, A. A., Berglund, L., Nakajima, K., Havel, P. J., & Stanhope, K. L. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8070913 · Cited by 28
“LDL cholesterol, oxidized LDL, and apoB and low levels of HDL-chol constitute the ‘atherogenic dyslipidemia complex’, a feature of type 2 diabetes and the metabolic syndrome [61].”
BackgroundThe Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction
Wang, X., Verma, S., Mason, R. P., & Bhatt, D. L. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01343-7 · Cited by 24
Lewis, G. F., & Hegele, R. A. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00284-9 · Cited by 27
Self-citationPradeilles, R., Norris, T., Sellem, L., & Markey, O. (2023) · Advances in Nutrition · doi:10.1016/j.advnut.2023.09.003 · Cited by 24
“Furthermore, the non-fasted state is important in the context of the pathogenesis and progression of cardiometabolic diseases, with elevated postprandial TG (which may re fl ect the atherogenic capacity of TG-rich lipoproteins) recognized as an independent CVD risk factor [21 – 23].”
BackgroundTan, H. L. E., McDonald, G., Payne, A. R., Yu, W., Ismadi, Z., Tran, H. A., Gani, J., & Wynne, K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123954 · Cited by 25
“This increase in FFA in combination with insulin resistance and decreased insulin signaling increases chylomicron secretion [30].”
BackgroundMulti-organ Coordination of Lipoprotein Secretion by Hormones, Nutrients and Neural Networks
Stahel, P., Xiao, C., Nahmias, A., Tian, L., & Lewis, G. F. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab008 · Cited by 26
Self-citationThe nature and characteristics of hypertriglyceridemia in a large cohort with type 2 diabetes
Echegoyen, F. F. B., Szeto, A., Mendez, A. J., Garg, R., & Goldberg, R. B. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108387 · Cited by 25
Antipsychotic-Induced Alterations in Lipid Turnover
Pereira, S., Au, E., Agarwal, S. M., Wright, D. C., & Hahn, M. (2023) · Endocrinology · doi:10.1210/endocr/bqad025 · Cited by 24
Al-Mhanna, S. B., Ghazali, W. S. W., Batrakoulis, A., Alkhamees, N. H., Drenowatz, C. J., Mohamed, M., Gülü, M., Afolabi, H. A., & Bădicu, G. (2024) · Annals of Applied Sport Science · doi:10.61186/aassjournal.1324 · Cited by 27
Hypolipidemic effects and mechanisms of Val-Phe-Val-Arg-Asn in C57BL/6J mice and 3T3-L1 cell models
Zhang, X., Shi, W., He, H., Cao, R., & Hou, T. (2020) · Journal of Functional Foods · doi:10.1016/j.jff.2020.104100 · Cited by 22
Cardiovascular Risk/Disease in Type 2 Diabetes Mellitus
Román, G., & Stoian, A. P. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.97422 · Cited by 30
Impact of protocatechuic acid on high fat diet-induced metabolic syndrome sequelae in rats
Nour, O. A., Ghoniem, H. A., Nader, M. A., & Suddek, G. M. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174257 · Cited by 21
Li, J., Bollati, C., Bartolomei, M., Mazzolari, A., Arnoldi, A., Vistoli, G., & Lammi, C. (2022) · Nutrients · doi:10.3390/nu14091804 · Cited by 25
“The increase of LDLR determines an enhanced clearance of plasmatic LDL-cholesterol with an improvement of dyslipidemia [7].”
BackgroundHyperlipidemia impacts osteogenesis via lipophagy
Ji, C., Zhang, Z., Xu, X., Song, D., & Zhang, D. (2022) · Bone · doi:10.1016/j.bone.2022.116643 · Cited by 20
Makena, W., Hambolu, J. O., Timbuak, J. A., Umana, U. E., Iliya, A. I., & Dibal, N. I. (2020) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-020-00648-4 · Cited by 23
Ulmus macrocarpa Hance modulates lipid metabolism in hyperlipidemia via activation of AMPK pathway
Han, H.-J., Song, X., Yadav, D., Hwang, M. S., Lee, J. H., Lee, C. H., Kim, T. H., Lee, J. J., & Kwon, J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217112 · Cited by 20
Mahmoud, A., Abdelsayed, K., Mohamed, A. A., Najah, Q., Abdulkader, A., Ali, K., Tabassum, S., Abouzid, M. R., Abdelazeem, B., & Mills, J. D. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-024-02389-2 · Cited by 17
Effects of Intranasal Insulin on Triglyceride-Rich Lipoprotein Particle Production in Healthy Men
Xiao, C., Dash, S., Stahel, P., & Lewis, G. F. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309705 · Cited by 17
Self-citationFeinkohl, I., Winterer, G., & Pischon, T. (2018) · Journal of Epidemiology & Community Health · doi:10.1136/jech-2017-210338 · Cited by 18
Jing, L., Li, L., Ren, X., Sun, Z., Bao, Z., Yuan, G., Cai, H., Wang, L., Shao, C., & Wang, Z. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s273029 · Cited by 16
High-density lipoprotein (HDL) cholesterol – more complicated than we think?
Nessler, K., Windak, A., Grzybczak, R., Nessler, M. B., Siniarski, A., & Gajos, G. (2018) · Annals of Agricultural and Environmental Medicine · doi:10.26444/aaem/92350 · Cited by 18
Yao, T., Lu, W., Ke, J., Zhang, H., Zhao, X., Song, B., Liu, T., Ke, Q., & Liu, C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.865863 · Cited by 16
Nan, G., Liu, L., Wu, H., Yin, S., Li, C., Zhao, H., Chen, H., & Wu, Q. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c05382 · Cited by 17
Faquih, T. O., Landstra, E. N., Vlieg, A. V. H., Aziz, N. A., Li‐Gao, R., de Mutsert, R., Rosendaal, F. R., Noordam, R., van Heemst, D., Mook-Kanamori, D. O., et al. (2024) · Exposure and Health · doi:10.1007/s12403-023-00622-4 · Cited by 19
“A higher lipid content of lipoproteins has been implicated in cardiovascular disease (CVD) (Xiao et al. 2016), while higher levels of fatty acids and apoB have been consistently associated with myocardial infarction (Julkunen et al. 2022).”
Cespiati, A., Rodrigues, I. C., Santos, I., Policarpo, S., Carvalhana, S. C., Fracanzani, A. L., & Cortez‐Pinto, H. (2024) · Liver International · doi:10.1111/liv.15876 · Cited by 22
Haslam, D. E., Chasman, D. I., Peloso, G. M., Herman, M. A., Dupuis, J., Lichtenstein, A. H., Smith, C. E., Ridker, P. M., Jacques, P. F., Mora, S., et al. (2022) · Journal of Nutrition · doi:10.1093/jn/nxac166 · Cited by 15
“This pattern is commonly observed among individuals with T2D and MetSyn (20, 21, 28, 29).”
Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome
Ahmad, M. I., & Shapiro, M. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00913-8 · Cited by 14
Jang, G., Sung, M. J., Hur, H. J., Yoo, M., Choi, J. H., Hwang, I. K., & Lee, S. H. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/5659174 · Cited by 15
Li, S., Zhao, X., Zhang, Y., Zhu, C., Guo, Y., Wu, N., Xu, R., Qing, P., Gao, Y., Sun, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12471 · Cited by 13
Pei, Z., Ji, J., Gao, Y., Wang, H., Wu, Y., Yang, J., Yang, Q., & Zhang, L. (2023) · Scientific Reports · doi:10.1038/s41598-023-36145-w · Cited by 12
Mukherjee, K., Wang, R., & Xiao, C. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.320032 · Cited by 12
Self-citationvan Meijeren, A. R., Ties, D., de Koning, M.-S. L. Y., van Dijk, R., van Blokland, I. V., Veloz, P. L., van Woerden, G., Vliegenthart, R., Pundziūtė, G., Westenbrink, B. D., et al. (2022) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2022.101006 · Cited by 13
Recent advances in cytoplasmic lipid droplet metabolism in intestinal enterocyte
Ghanem, M., Lewis, G. F., & Xiao, C. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159197 · Cited by 15
Self-citationTarboush, F., Alsultan, M. K., & Alourfi, Z. (2023) · Medicine · doi:10.1097/md.0000000000034959 · Cited by 15
“23] Also, the decreased LDL-receptors’ activity resulting in decreased catabolism of LDL. [24,25] Moreover, this population may also present with elevated TG and VLDL levels due to decrease the activity of lipoprotein lipase that found in overt hypothyroidism.”
Background
Metadata
- Authors
- Xiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F.
- Affiliations
- University of Toronto (CA)
- Western University (CA)
- Corresponding author
- Lewis, Gary F.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2016-06-13
- Volume
- 65
- Issue
- 7
- Pages
- 1767-1778
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2472281584
- Cited by
- 212
- References
- 137
- Citations by year
- 2026: 6 · 2025: 21 · 2024: 20 · 2023: 20 · 2022: 34 · 2021: 35 · 2020: 23 · 2019: 25 · 2018: 13 · 2017: 12 · 2016: 2
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (MOP‑79533), MOP13430, MOP-43839)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- residual cardiovascular risk, hypertriglyceridemia, low HDL cholesterol, remnant lipoproteins, postprandial lipemia, triglyceride-rich lipoproteins, insulin resistance, type 2 diabetes, obesity, fibrates, nicotinic acid, cholesteryl ester transfer protein inhibitors, drug repurposing, cardiovascular disease prevention
- MeSH terms
- Hypolipidemic Agents, Cardiovascular Diseases, Humans, Cholesterol, LDL, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.